ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,422.00
      0.10%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.785
      1.05%
      Bitcoin
      65,096.68
      -2.09%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Esperion Therapeutics Inc (ESPR)

      7. Esperion Therapeutics Inc (ESPR) News

      ESPR

      Esperion Therapeutics (ESPR)

      Esperion Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ESPR
      DateTimeSourceHeadlineSymbolCompany
      04/13/20234:11PMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ESPREsperion Therapeutics Inc
      04/03/20234:14PMEdgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ESPREsperion Therapeutics Inc
      04/03/20238:00AMGlobeNewswire Inc.Esperion to Participate in Needham 22nd Annual Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
      03/22/20234:41PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ESPREsperion Therapeutics Inc
      03/22/20234:36PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ESPREsperion Therapeutics Inc
      03/22/20234:15PMGlobeNewswire Inc.Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:ESPREsperion Therapeutics Inc
      03/21/20234:06PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ESPREsperion Therapeutics Inc
      03/20/20234:20PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/20/20234:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/20/20234:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/20/20238:00AMGlobeNewswire Inc.Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:ESPREsperion Therapeutics Inc
      03/15/20234:27PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ESPREsperion Therapeutics Inc
      03/15/20239:23AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/15/20239:23AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/10/20234:32PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ESPREsperion Therapeutics Inc
      03/08/20234:23PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/08/20234:23PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/08/20234:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ESPREsperion Therapeutics Inc
      03/08/20238:00AMGlobeNewswire Inc.International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular RiskNASDAQ:ESPREsperion Therapeutics Inc
      03/07/20233:32PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ESPREsperion Therapeutics Inc
      03/06/20239:47AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ESPREsperion Therapeutics Inc
      03/04/202310:30AMGlobeNewswire Inc.Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention PatientsNASDAQ:ESPREsperion Therapeutics Inc
      02/24/20231:40PMGlobeNewswire Inc.Esperion Launches New Scientific WebsiteNASDAQ:ESPREsperion Therapeutics Inc
      02/23/20238:00AMGlobeNewswire Inc.Esperion to Participate in the Cowen 43rd Annual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
      02/22/20238:00AMGlobeNewswire Inc.CLEAR Outcomes Company Update Call: Detailed Results DiscussionNASDAQ:ESPREsperion Therapeutics Inc
      02/21/20234:07PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ESPREsperion Therapeutics Inc
      02/21/20239:26AMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:ESPREsperion Therapeutics Inc
      02/21/20237:00AMGlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company UpdateNASDAQ:ESPREsperion Therapeutics Inc
      02/20/20238:00AMGlobeNewswire Inc.Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCCNASDAQ:ESPREsperion Therapeutics Inc
      02/13/20234:30PMGlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ESPR